WatchlistSix Spanish biotech startups to watch in 2026The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, … more ➔
drug deliveryCell therapies: breaking barriers in solid tumoursIt’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable therapy against tumours. But when it comes to fighting solid tumours, … more ➔
EntrepreneurshipThe Strüngmann legacy, passed onThomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family … more ➔
BioNTech SEOncologyBioNTech adds clinical weight to its oncology pivot at WCLC 2026New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously … more ➔
Drug deliveryInside exosomes: Nature’s drug carriersNext-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding … more ➔
NeurologyHow biotech is treating epilepsy beyond seizuresFor decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and … more ➔
TecanLab automationThe emergence of agentic AI in lab automationThere’s uncertainty and concern about whether AI will replace humans in workplaces. But Marco Ravot-Licheri, Head of Digital – Life Sciences Business at Tecan, told us that AI could increase laboratory … more ➔
RegulatoryFast-track trial approval: a way to jump the EU queue?Launched in 2022, the EU Clinical Trials Information System (CTIS) aims to streamline and centralise the process of applying for clinical trial authorisation, but has also increased typical approval … more ➔
TechnologiesRNA medicine enters its second actThe COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing … more ➔
Bayer AGBayerBayer rebuilds pharma while waiting for Monsanto reliefA stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation. more ➔
BioNTech SE
Tecan
Bayer AG